These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20662626)

  • 1. Burden of illness among patients at high risk versus low risk for major cardiovascular events.
    Harley C; Sander SD; Zarotsky V; Cao F; Shah H
    J Med Econ; 2010; 13(3):438-46. PubMed ID: 20662626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
    Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
    J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population.
    Alemayehu B; Buysman E; Parry D; Becker L; Nathan F
    J Med Econ; 2010; 13(2):351-61. PubMed ID: 20491610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care.
    Chew DP; Astley C; Molloy D; Vaile J; De Pasquale CG; Aylward P
    Intern Med J; 2006 Mar; 36(3):185-92. PubMed ID: 16503954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care utilization & costs for cystic fibrosis patients with pulmonary infections.
    O'Sullivan AK; Sullivan J; Higuchi K; Montgomery AB
    Manag Care; 2011 Feb; 20(2):37-44. PubMed ID: 21428129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus.
    Zhao Z; Zhu B; Anderson J; Fu H; LeNarz L
    J Med Econ; 2010; 13(4):748-59. PubMed ID: 21091396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of change in high-density lipoprotein cholesterol from baseline on risk for major cardiovascular events.
    Laitinen DL; Manthena S
    Adv Ther; 2010 Apr; 27(4):233-44. PubMed ID: 20437214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
    Joyce AT; Smith P; Khandker R; Melin JM; Singh A
    J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs.
    Daviglus ML; Liu K; Greenland P; Dyer AR; Garside DB; Manheim L; Lowe LP; Rodin M; Lubitz J; Stamler J
    N Engl J Med; 1998 Oct; 339(16):1122-9. PubMed ID: 9770560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB
    J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and expenditures of women diagnosed with hypoactive sexual desire disorder.
    Foley K; Foley D; Johnson BH
    J Med Econ; 2010; 13(4):583-90. PubMed ID: 20831458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotection: what is it? Who needs it?
    Kannel WB
    Am J Manag Care; 2002 Jun; 8(9 Suppl):5-12. PubMed ID: 12099329
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost minimization analysis of low back pain claims data for chiropractic vs medicine in a managed care organization.
    Grieves B; Menke JM; Pursel KJ
    J Manipulative Physiol Ther; 2009; 32(9):734-9. PubMed ID: 20004800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges for the management of hypertension in low-resource settings.
    Mendis S
    Ethn Dis; 2003; 13(2 Suppl 2):S67-70. PubMed ID: 13677416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.